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A B S T R A C T
Exposure to contaminants can lead to accumulation of lipids in the liver. This study aimed to examine whether
eicosapentaenoic acid (EPA) and arachidonic acid (ARA) supplementation can protect fish cells against the
negative impact of chlorpyrifos (CPF). Atlantic salmon hepatocytes were exposed to either 100 μM CPF, 200 μM
EPA, 200 μM ARA, or combinations of these for 48 h, and endpoints included lipid droplet formation, gene
expression, and global metabolomic analysis. The results showed that polyunsaturated fatty acid (PUFA) sup-
plementation modified the cell lipid composition, reduced uptake of CPF and increased the cellular number and
size of lipid droplets. CPF exposure induced the transcription of ppara and fabp3, and reduced the levels of
several PUFAs, and lead to accumulation of monoacylglycerols (MAGs) in the cells. Supplementation of EPA or
ARA did not prevent CPF-induced accumulation of MAGs and only to a limited degree rescued the response on
other lipids. CPF exposure further reduced energy metabolism, a response partly restored by PUFA supple-
mentation. Reduced levels of glutathione indicated oxidative stress; an effect not ameliorated by the PUFAs.
Altogether, this study shows that PUFA supplementation only modestly protects Atlantic salmon hepatocytes
against the negative impact of CPF.
1. Introduction
Accumulating evidence suggests that exposure to persistent organic
pollutants (POPs) is associated with accumulation of fat in the liver
(Grun and Blumberg, 2007; Al-Eryani et al., 2015; Darbre, 2017). En-
docrine-disrupting chemicals in particular are linked to fatty liver, due
to their ability to bind to and interfere with nuclear receptors (Foulds
et al., 2017). Fatty liver occurs when hepatic uptake and/or de novo
synthesis of free fatty acids exceeds their oxidation and secretion as
triglycerides (TAGs) (Foulds et al., 2017). Abnormal accumulation of
lipids in the liver has been proposed to be among the most common
pathologic hepatic responses to chemical exposure (Cave et al., 2011).
In hepatic steatosis, excess TAG is usually stored in lipid droplets sized
between 50 nm and 1 μm within the hepatocyte (Sahini and Borlak,
2014). The number and size of lipid droplets, typically present in the
cytosol, are well-established histological biomarkers of fatty liver
(Willebrords et al., 2015). Excessive synthesis and accumulation of TAG
is not necessarily hepatotoxic, but imbalance of free fatty acid meta-
bolism in the hepatocytes may lead to hepatocellular damage, often by
initiating a pro-inflammatory cascade (Foulds et al., 2017). Fish studies
indicate that the mechanisms underlying the development of fatty liver
are conserved across phyla (Zang et al., 2018). In zebrafish (Danio
rerio), it has been shown that excess nutrients cause increased plasma
TAG and hepatic steatosis (Oka et al., 2010). In Atlantic salmon (Salmo
salar), liver TAG accumulation has been associated with excessive in-
take of n-6 fatty acids due to replacement of marine ingredients with
plant ingredients in the diet (Torstensen et al., 2011; Alvheim et al.,
2013; Sanden et al., 2016).
Interestingly, some n-3 polyunsaturated fatty acids (PUFAs) with
anti-inflammatory properties, such as eicosapentaenoic acid (EPA),
docosahexaenoic acid (DHA) and α-linolenic acid (ALA), seem to re-
duce the degree of fat accumulation in the liver. For example, supple-
mentation of EPA can inhibit hepatic steatosis in obese mice (Inoue-
Yamauchi et al., 2018). Similar findings have been reported for fish.
High levels of the DHA and EPA in the diet protect against nutrient-
derived induction of fatty liver in Atlantic salmon (Liland et al., 2013,
2015). Other n-6 PUFAs can have the opposite effects, and act pro-in-
flammatory. Arachidonic acid (ARA) is metabolized to both pro-
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inflammatory and anti-inflammatory eicosanoids. For example, ARA-
derived metabolites of the cyclooxygenase (COX) pathway are generally
considered to be pro-inflammatory (Cranmer-Byng et al., 2015). ARA
may also enhance oxidative stress by non-enzymatic free radical-in-
itiated peroxidation reactions (Vigor et al., 2014). In Atlantic salmon
hepatocytes, we have previously shown that while EPA can help protect
cells against the negative effects of contaminants, ARA contrarily seems
to strengthen the contaminant-induced response (Søfteland et al.,
2016). Enhanced protection against contaminant damage has also been
demonstrated in rainbow trout (Oncorhynchus mykiss) liver cells after
PUFA supplementation (Ferain et al., 2016).
In a series of examinations, we have been studying the potential
toxicity of agricultural pesticides found in aquafeeds on Atlantic
salmon. Sustainable aquafeeds used today contain higher levels of plant
ingredients, with more of the n-6 ARA precursor linoleic acid (LA) and
less n-3 EPA and DHA, compared to earlier feeds for salmon that con-
sisted primarily of marine ingredients. These studies have focused on
the organophosphorus pesticides (OPs) chlorpyrifos (CPF), chlorpyr-
ifos-methyl (CPM) and pirimiphos-methyl (PPM) (Olsvik et al., 2015,
2017, 2019a; Søfteland et al., 2016; Sanden et al., 2018). One of the
main effects of OPs in salmon, both after short-term in vitro exposure
and after longer-term in vivo exposure, is the disruption of lipid meta-
bolism (Søfteland et al., 2016; Sanden et al., 2018). Exposure to OPs
typically leads to depletion of long-chain fatty acids and PUFAs, and
accumulation of monoacylglycerols (MAGs). Pathway analysis often
points to mechanisms linked to accumulation of lipids and steatosis as
the main disease and function. Compared to POPs, OPs are more easily
biodegraded, and less is known about how these chemicals interfere
with lipid metabolism in fish.
In light of this, the aim of this study was to examine to which degree
EPA supplementation protects cells against CPF-induced disruption of
lipid metabolism, and whether ARA co-supplementation interfere with
the potential protective effect of EPA in Atlantic salmon hepatocytes.
Other mechanisms potentially impacted by PUFA supplementation,
such as detoxification and oxidative stress, were also studied.
2. Material and methods
2.1. In vitro exposure experiment
Hepatocytes were isolated from male Atlantic salmon (n=6,
669 ± 141 g, mean ± st.dev.) with a two-step perfusion method as
previously described by Søfteland et al. (2009). After isolation, cell
viability was evaluated with the Trypan Blue (Lonzo, Medprobe, Oslo,
Norway) exclusion method. Prior to exposure, the cells were cultured
for 36–40 h in L-15 medium containing 10% salmon serum (Nordic
BioSite, Oslo, Norway), with change of medium after 18–20 h. The cell
suspensions were plated on laminin-coated (5 μg/cm2) plates and
chamber slides. Cells were exposed in 6-well plates for metabolomics, in
12-well plates for gene expression analysis (RT-qPCR), and in 96-well
plates for cytotoxicity determination (MTT and xCELLigence). Quanti-
fication of lipid accumulation with the Oil Red O colorimetric assay was
done in 96-well plates, whereas 8-well chamber slides were used for Oil
Red O lipid droplet staining. The following cell densities were used;
7.2× 106 cells per well in 3mL L-15 medium for metabolomics,
2.6× 106 cells per well for gene expression analysis, 0.2× 106 cells per
well in 0.2mL L-15 medium for determination of cytotoxicity and lipid
accumulation, and 0.4× 106 cells per well in 0.5 mL L-15 medium for
lipid droplet staining. The L-15 exposure medium, containing 1%
salmon serum, was changed after 18–20 h. The number of biological
replicates was n=6.
Based on previous work in our laboratory including individual cy-
totoxicity dose-response curves for CPF and the fatty acids, the hepa-
tocytes were treated with 100 μM CPF, 200 μM of ARA and 200 μM EPA
in this study (Søfteland et al., 2016, unpublished work). The treatment
1:1 ratio between ARA and EPA was selected based on earlier in vitro
studies with salmon hepatocytes using combinations of similar con-
centrations of ARA and EPA (Søfteland et al., 2016), and in vivo studies
with salmon (Sissener et al., unpublished work). CPF was dissolved in
dimethyl sulfoxide (DMSO) (Scientific and Chemical Supplies Ltd.,
Bilston, UK). All exposure solutions contained equal amounts of DMSO
(0.2%). The fatty acids were purchased from Sigma Chemical Co (St
Louis, MO, USA). Binding of fatty acids to fatty acid free-BSA
(FAF–BSA) was performed as per Ghioni et al. (1997). To summarize,
fatty acids dissolved in 0.04mL chloroform per mg fatty acid was added
to a glass sample tube and N2 was used to evaporate the chloroform.
Potassium hydroxide (KOH) was applied to the fatty acid in a 1:3 ratio
and the solution was shaken for 10min using a vortex mixer. FAF–BSA
was employed in a 2.5:1 relationship to the fatty acid and the solution
was mixed for 45min before it was sterile-filtered and preserved at
−80 °C in anoxic condition. Unless otherwise noted, chemicals were
obtained from Sigma-Aldrich (Oslo, Norway).
2.2. Cytotoxicity screening
Cell viability was determined with the MTT-based In Vitro
Toxicology assay (Sigma Aldrich). After 48 h of exposure, the cells were
incubated with MTT, and the absorbance at 570 nm was determined
with an iEMS reader (Labsystems iEMS Reader MF, Helsinki, Finland).
The xCELLigence system (Real-Time Cell Analyzer RTCA-SP, ACEA
Biosciences, San Diego, USA) was used for impedance-based real-time
detection of cell viability (Ke et al., 2011). The data was collected with
2min intervals for 12 h, and then every 15min for about 60 h.
2.3. Quantification of lipid droplets and staining of neutral lipids in
hepatocytes
For evaluation of the extent of lipid accumulation, the hepatocytes
were stained with Oil Red O using a colorimetric assay (Cayman
Chemical, Ann Arbor, MI, USA). For quantification of lipid accumula-
tion, 100 μL of the Lipid Droplets Assay Dye Extraction Solution was
added to the cells. After gently mixing for 30min, the samples were
transferred to a 96-well plate and the absorbance read at 490 nm with a
96-well plate reader. For histological evaluation of lipid droplet dis-
tribution and size, hepatocytes were rinsed with 1xPBS and fixed using
4% paraformaldehyde for 15min at room temperature. The cells were
washed with 1xPBS and air dried, and then stained with Oil Red O for
30min at room temperature before microscopy examination. Lipid
droplets were examined at 20× magnification (Olympus BX51 micro-
scope with UPlanFL N 20× objective, Tokyo, Japan) connected to a
CCD camera, using NIS-Elements software.
2.4. RNA isolation and RT-qPCR
The RNeasy Plus mini kit (Qiagen, Crawley, UK) was used to extract
total RNA from the hepatocytes. RNA quality was assessed using the
NanoDrop ND-1000 UV–Vis Spectrophotometer (NanoDrop
Technologies, Wilmington, DE, USA) and the Agilent 2100 Bioanalyzer
(Agilent Technologies, Palo Alto, CA, USA). The RNA integrity number
(RIN) for 12 randomly selected samples used for gene expression ana-
lysis was 9.7 ± 0.1 (mean ± st.dev.).
A two-step real-time RT-qPCR protocol was used to quantify the
mRNA levels of 9 target genes and 2 reference genes. Target gene mean
normalized expression (MNE) was determined using the geNorm soft-
ware (Vandesompele et al., 2002) and a normalization factor based
upon rplp0 and eef1b1 (M < 0.43). Supplementary Table S1 shows
gene names and PCR assays.
2.5. Protein extraction and western blot
To harvest proteins from cell cultures, the CelLytic M Cell Lysis
Reagent was used. Microsomal fractions from the cell lysate were
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prepared with differential centrifugation. After centrifugation at
12,000×g for 20min at 4 °C, the supernatant S-12 fraction was col-
lected. The microsomal fraction was collected by centrifugation of the
S-12 fraction at 100,000×g for 60min at 4 °C. Protein enrichment was
ensured by using the Amicon Ultra-0.5 Centrifugal Filter 10 K Devices
from Merck Millipore (Darmstadt, Germany). Quantification of total
protein was done with the Pierce 660 nm Protein colorimetric assay
(Thermo Scientific, Rockford, USA) using protein standards made of
bovine serum albumin (BSA). The absorbance at 660 nm was measured
spectrophotometrically using a 96-well plate reader.
After SDS-PAGE (10% SDS-gels) using BioRad MiniProtean Cell,
proteins were transferred to a PVDF membrane using the Trans-Blot
Turbo RTA Transfer kit (BioRad, California, USA). After protein
transfer, the membrane was blocked with 3% BSA in 1× PBS for 60min
at room temperature at continuous shaking. Primary antibodies used
for the detection of cytochrome P450 1A (CYP1A) and β-actin (control)
were applied to the membrane and incubated overnight at continuous
shaking at 4 °C. After second incubation the membrane was rinsed three
times for 5min with 1× PBS and the secondary antibody (anti-rabbit
conjugated to HRP) diluted 1:1000 in 2% ECL in 1× PBS was added.
The membrane was then incubated for 2 h at continuous shaking. After
the third incubation the membrane was rinsed again five times for
5min with 1× PBS. The PVDF membrane was then exposed to
Amersham ECL Western Blotting Detection Reagent (GE Healthcare) for
visualization of immunoreactive proteins, using a ChemiDoc camera
(G:BOX, Syngene, Cambridge, United Kingdom). Densitometric data
analysis was done using the ImageJ software. Because β-actin was
regulated by the treatment and could not be used for normalization, the
total protein stock pooled from all samples was used for normalization
purpose.
2.6. Metabolite analysis
Global metabolite profiling was conducted as previously described
by Olsvik et al. (2015). Briefly, samples prepared using the automated
MicroLab STAR® (Hamilton Company, Reno, NV, USA) were divided
into 5 fractions: one for analysis by Ultrahigh Performance Liquid
Chromatography-Tandem Mass Spectroscopy (UPLC-MS/MS) with po-
sitive ion mode electrospray ionization, one for analysis by UPLC-MS/
MS with negative ion mode electrospray ionization, one for LC polar
platform, one for analysis by Gas Chromatography-Mass Spectroscopy
(GC–MS), and one sample was reserved for backup. The LC/MS portion
of the platform was based on a Waters ACQUITY ultra-performance
liquid chromatography (UPLC) and a Thermo Scientific Q-Exactive high
resolution/accurate mass spectrometer interfaced with a heated elec-
trospray ionization (HESI-II) source and Orbitrap mass analyzer oper-
ated at 35,000 mass resolution. The GC–MS portion of the platform was
based on a Thermo-Finnigan Trace DSQ fast-scanning single-quadru-
pole mass spectrometer using electron impact ionization (EI) and op-
erated at unit mass resolving power.
2.7. Statistics
One-way or two-way ANOVA with Holm-Sidak's posttest was used
for comparison between the treatment groups. Brown-Forsythe and
Bartlett's tests were used for evaluation of homogeneity of variances,
and the values were log-transformed before ANOVA if deemed neces-
sary. Spearman's rank correlation analysis was used to search for pos-
sible co-regulation among the parameters. The GraphPad Prism 8.0
(GraphPad Software, Inc., San Diego, CA, USA) was used for statistical
analyses of the data. Following normalization to total protein (Bradford
assay) and log transformation, and imputation of missing values, if any,
with the minimum observed value for each compound, ANOVA con-
trasts were used to identify metabolites that differed significantly be-
tween experimental groups. Welch's two-sample t-tests were used to
identify metabolites that differed significantly between experimental
groups (p < .05). Statistical analyses of the log-transformed data were
performed with the program “R” (The Comprehensive R Archive
Network). Functional pathway analyses were generated through the use
of Qiagen's Ingenuity® Pathway Analysis (IPA®, Qiagen Redwood City,
www.qiagen.com/ingenuity). IPA Upstream Regulator analytic was
used to identify the cascade of upstream transcriptional regulators that
can explain the observed expression changes in the datasets.
3. Results
3.1. No effect on cytotoxicity
After extraction, the cell viability was 96 ± 2% (n=6, mean ±
st.dev.) as determined with the Trypan Blue exclusion method. After
48 h of exposure, no significant effect of CPF treatment was observed on
cytotoxicity measured with the MTT assay or with the xCELLigence
system (Fig. S1). Supplementation of ARA or EPA, alone or in combi-
nation with CPF, neither had any significant effect on cytotoxicity
compared to the control.
3.2. Modified lipid composition of hepatocytes supplemented with PUFAs
Supplementation of ARA and EPA in the exposure medium had a
distinct effect on the PUFA profiles of the Atlantic salmon primary cells.
Table 1 shows the concentrations of n-3 and n-6 PUFAs in the hepato-
cytes. Fig. 1 shows principal component analysis (PCA) plots of the sum
of n-3 (Fig. 1A) and n-6 (Fig. 1B) PUFAs in the cells after the different
treatments. Treatment with ARA for 48 h significantly increased the
concentration of n-6 PUFAs ARA (20:4, 8.5-fold), adrenate (docosate-
traenoic acid), (22:4, 38.2-fold), and docosapentaenoate (22:5, 7.5-
fold), and decreased linoleate (18:2, −1.9-fold). Treatment with ARA
also increased the level of dihomo-linolenate (20:3, n-3 or n-6, 1.6-fold)
and decreased the level of n-3 docosahexaenoate (DHA; 22:6, −1.6-
fold). Similarly, treatment with EPA for 48 h increased the levels of n-3
PUFAs EPA (20:5, 4.3-fold), docosapentaenoate (DPA; 22:5, 6.7-fold)
and stearidonate (18:4, 1.5-fold). Treatment with EPA also significantly
decreased the levels of linolenate (LA, alpha or gamma, 18:3 n-3 or n-6,
−2.2-fold) and docosapentaenoate (DPA; 22:5, −2.1-fold). Supple-
mentation of ARA or EPA in the culture medium for 48 h significantly
changed the fatty acid composition of the Atlantic salmon hepatocytes
as intended.
3.3. Steatosis assay and evaluation of lipid droplet formation
Compared to the control, no significant effect of the treatments was
seen on steatosis as quantified with the Cayman Steatosis Colorimetric
Assay (Fig. 2A). Posthoc tests showed a significant difference in lipid
accumulation between cells exposed to CPF and those co-treated with
CPF and both PUFAs (one-way ANOVA, p= .0372). The degree of lipid
accumulation in Atlantic salmon liver cells correlated significantly with
the transcriptional levels of peroxisome proliferator activated receptor
alpha (ppara) (Fig. 2C) and the concentration of DHA and LA (Spear-
man's rank correlation, ppara: p= .002, r=0.34; n-3 DHA: p= .03,
r=0.20 and n-6 LA: p= .031, r=0.22).
Three methodological approaches were used to examine how CPF,
ARA and EPA affect lipid droplet accumulation and morphology. First
by examining the visible impact on overall histology, secondly by the
quantification of total number and area of lipid droplets and thirdly by
a quantitative assessment of lipid droplet size. Fig. 3 shows re-
presentative images of lipid droplets in the hepatocytes after treatment.
From the images, it can clearly be seen that ARA and EPA supple-
mentation, alone or in combination with CPF, strongly impacts lipid
droplet formation (Fig. 3C–G). Exposure to CPF alone (Fig. 3B) also
appears to slightly increase lipid formation in the hepatocytes. In ad-
dition, there were noticeably larger sized lipid droplets in hepatocytes
exposed individually to ARA and EPA, and the different combinations
P.A. Olsvik, et al. Toxicology in Vitro 61 (2019) 104655
3
of CPF, ARA and EPA, compared to the control group. Fig. 4A shows the
total number of lipid droplets in equally sized and squared areas of the
images. Compared to the control, all treatment groups that received
PUFAs had significantly higher number of lipid droplets. Exposure to
CPF alone did not significantly increase the number of lipid droplets in
the cells. Quantitative examination of the total area of lipid droplets
yielded the same pattern, with larger areas covered by lipid droplets in
cells treated with PUFAs (Fig. 4B). Size distribution of lipid droplets are
shown in Table 2. For small-sized lipid droplets (< 0.5 μm2), the
treatment reduced the number of lipid droplets in the CPF+ARA and
CPF+EPA groups compared to the control (one-way ANOVA,
p < .01). For the medium-sized range (5–15 μm2), treatment with
ARA, CPF+ARA and CPF+EPA increased the number of lipid dro-
plets (p < .05). No significant differences were observed for large-sized
(15–30 μm2) and very large-sized (> 30 μm2) lipid droplets.
3.4. Ppara and fabp3 transcription affected by chlorpyrifos
Of 9 examined target genes, only 2 showed a significant induction
after CPF treatment. For ppara (Fig. 2C) and fatty acid binding protein 3
(fabp3) (Fig. 2D) there were significant effects of CPF treatment (2-way
ANOVA, ppara: p= .0029, fabp3: p= .0036). No significant interaction
effect of co-treatment with ARA or EPA was seen on the transcription of
these genes. Although not significant, for ppara it appeared that co-
treatment with EPA but not ARA weakened the CPF-induced effect. For
cyp1a1 transcription (Fig. 2E), there was a significant effect of ARA and
EPA treatment (reduced transcriptional levels) (2-way ANOVA, ARA:
p= .0207, EPA: p= .0159), but no interaction effect with CPF and the
PUFAs, or effect of CPF alone. According to the 2-way ANOVA result, a
significant effect of ARA treatment was also seen on daf36 (2-way
ANOVA, p= .0075), but again with no interaction effect with CPF (Fig.
S2F). No significant effects were seen for cyp3a, vtg1, cpt1a, acox1 and
rara (Fig. S2).
Table 1
Profile of polyunsaturated fatty acids (PUFAs) in Atlantic salmon hepatocytes after 48 h exposure to chlorpyrifos (CPF) and supplementation with 200 μM arachidonic
acid (ARA) or eicosapentaenoic acid (EPA) (values based on raw area counts normalized by Bradford protein).
Polyunsaturated fatty acid Control CPF ARA CPF+ARA EPA CPF+EPA CPF+ARA+EPA
n-3 PUFAs
Stearidonate (18:4n-3) 1.574 ± 0.495 0.727 ± 0.198⁎⁎ 1.671 ± 0.532 0.814 ± 0.142⁎⁎ 2.387 ± 0.590 0.876 ± 0.233⁎ 0.805 ± 0.257⁎⁎
Eicosapentaenoate (EPA; 20:5n-
3)
0.817 ± 0.145 0.462 ± 0.114⁎⁎⁎ 0.876 ± 0.222 0.443 ± 0.055⁎⁎⁎ 3.504 ± 1.145⁎⁎⁎⁎ 2.222 ± 0.545⁎⁎⁎⁎ 2.295 ± 0.365⁎⁎⁎⁎
Docosapentaenoate (DPA;
22:5n-3)
0.932 ± 0.278 0.389 ± 0.096⁎⁎⁎ 1.065 ± 0.462 0.284 ± 0.061⁎⁎⁎⁎ 6.199 ± 2.418⁎⁎⁎⁎ 2.712 ± 1.010⁎⁎⁎⁎ 1.496 ± 0.516
Docosahexaenoate (DHA; 22:6n-
3)
2.794 ± 0.630 0.969 ± 0.251⁎⁎⁎⁎ 1.716 ± 0.495⁎⁎ 0.364 ± 0.076⁎⁎⁎⁎ 2.791 ± 0.761 0.579 ± 0.166⁎⁎⁎⁎ 0.321 ± 0.054⁎⁎⁎⁎
Docosatrienoate (22:3n-3) 1.622 ± 0.780 0.885 ± 0.339 3.486 ± 2.709 1.430 ± 0.943 1.349 ± 0.583 0.426 ± 0.195⁎⁎⁎ 0.414 ± 0.173⁎⁎⁎
n-3 or n-6 PUFAs
Linolenate (alpha or gamma;
18:3n-3 or n-6)
1.778 ± 0.479 1.009 ± 0.211⁎⁎ 1.835 ± 0.484 1.046 ± 0.096⁎⁎ 0.824 ± 0.163⁎⁎⁎⁎ 0.453 ± 0.101⁎⁎⁎⁎ 0.485 ± 0.133⁎⁎⁎⁎
Dihomo-linolenate (20:3n-3 or
n-6)
1.336 ± 0.241 0.789 ± 0.126⁎⁎ 2.180 ± 0.842⁎⁎ 1.209 ± 0.212 1.131 ± 0.172 0.503 ± 0.068⁎⁎⁎⁎ 0.690 ± 0.150⁎⁎⁎⁎
n-6 PUFAs
Arachidonate (ARA; 20:4n-6) 0.746 ± 0.220 0.397 ± 0.099⁎⁎⁎ 6.336 ± 1.562⁎⁎⁎⁎ 5.165 ± 0.906⁎⁎⁎⁎ 0.826 ± 0.224 0.386 ± 0.083⁎⁎⁎ 4.341 ± 0.490⁎⁎⁎⁎
Adrenate (22:4n-6) 0.795 ± 0.337 0.289 ± 0.188⁎⁎⁎ 30.33 ± 9.125⁎⁎⁎⁎ 16.41 ± 2.844⁎⁎⁎⁎ 0.981 ± 0.406 0.473 ± 0.279 7.780 ± 2.141⁎⁎⁎⁎
Linoleate (18:2n-6) 1.880 ± 0.411 1.397 ± 0.316 0.973 ± 0.350⁎⁎⁎ 0.637 ± 0.123⁎⁎⁎⁎ 1.472 ± 0.313 0.946 ± 0.171⁎⁎⁎ 0.519 ± 0.106⁎⁎⁎⁎
Docosapentaenoate (DPA;
22:5n-6)
0.592 ± 0.247 0.430 ± 0.102 4.457 ± 2.612⁎⁎⁎⁎ 1.422 ± 0.561⁎⁎⁎ 0⁎a 0⁎a 0⁎a
Docosadienoate (22:2n-6) 2.142 ± 1.327 1.422 ± 0.647 1.646 ± 0.669 0.670 ± 0.087⁎⁎⁎ 1.481 ± 0.432 0.504 ± 0.099⁎⁎⁎⁎ 0.422 ± 0.089⁎⁎⁎⁎
Dihomo-linoleate (20:2n-6) 2.075 ± 0.784 1.200 ± 0.358⁎ 1.474 ± 0.599 0.763 ± 0.096⁎⁎⁎⁎ 1.339 ± 0.218 0.626 ± 0.122⁎⁎⁎⁎ 0.505 ± 0.151⁎⁎⁎⁎
Stars indicate significant differences as compared to the control (one-way ANOVA with Holm-Sidak's multiple comparisons test, using log-transformed data,
⁎p < .05, ⁎⁎p < .01, ⁎⁎⁎p < .001, ⁎⁎⁎⁎p < .0001). Data are expressed as means ± st.dev. (n=6).
a Below detection limit, missing values are imputed with the minimum.
Fig. 1. Principal component analysis (PCA) showing treatment effects on (A) sum of n-3 fatty acids (∑ EPA, DHA, n-3 DPA, SDA and docosatrienoate (22:3) and (B)
sum of n-6 fatty acids (∑ ARA, n-6 DPA, adrenate (22:4), dihomo-linoleate (20:2), docosadienoate (22:2), linoleate (18:2)).
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Fig. 2. (A) Steatosis in Atlantic salmon hepatocytes exposed to chlorpyrifos (CPF) alone or in combination with arachidonic acid (ARA) and eicosapentaenoic acid
(EPA) determined with a colorimetric assay. (B) CPF levels in exposed cells, (C) ppara gene expression, (D) fabp3 gene expression, (E) cyp1a1 gene expression and (F)
CYP1A protein level. Significance levels (two-way ANOVA, Holm-Sidak's post-test) are shown in the figures. ⁎p < .05, ⁎⁎p < .01. For the comparison between the
control and CPF+ARA+EPA group, significance is shown based on the t-test. Values are mean ± st.dev. (n=6).
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3.5. No effect on CYP1A protein level
No significant effects were seen for CYP1A (Fig. 2F) protein content
in the cells after the different treatments.
3.6. Impact of PUFAs on metabolites
A total of 330 metabolites with known ID were detected in the
Atlantic salmon hepatocytes. Table 3 shows a summary of the numbers
of metabolites and biochemicals that achieved statistical significance
(p≤ .05). Overlapping metabolites are shown in Fig. 5A, B. Supple-
mentary File 2 shows all individual metabolites that were significantly
affected by the various treatments. Principal component analysis re-
vealed a certain degree of heterogeneity within the controls and in the
group exposed to CPF (data not shown), potentially suggesting
differences in basal metabolism between individual primary-derived
cell samples or CPF induced differences in cellular metabolism. Hier-
archical clustering still showed a relatively clear separation between
the groups that received CPF or not (Fig. 5C). Combinatorial treatment
with CPF resulted in a shift compared to single treatment alone and may
reflect an additive or synergistic impact on global metabolism.
IPA Upstream Regulator analytic was used to identify the cascade of
upstream transcriptional regulators that can explain the observed
changes in the datasets. A combined list of significant genes and me-
tabolites were used as input for the IPA analyses. Predicted upstream
regulators are shown in Supplementary File 3.
3.6.1. PUFA supplementation reduces chlorpyrifos accumulation
The metabolic profiling documented significant accumulation of
CPF in hepatocytes after 48 h of treatment (Fig. 2B). Cells that were co-
Fig. 3. Representative microscopy images of primary
hepatocytes from Atlantic salmon exposed to chlor-
pyrifos (CPF), arachidonic acid (ARA) and eicosa-
pentaenoic acid (EPA) individually or in combina-
tion and stained with Oil Red O. (A) Control, (B) CPF
(100 μM), (C) ARA (200 μM), (D) CPF
(100 μM)+ARA (200 μM), (E) EPA (200 μM), (F)
CPF (100 μM)+EPA (200 μM), and (G) CPF
(100 μM)+ARA (200 μM)+EPA (200 μM). The
presented images are representative for the mor-
phological changes seen in different exposure groups
(n=6). The magnification was set to 20×, scale
bar= 100 μm, picture resolution 4.1681 pixel/μm.
(For interpretation of the references to colour in this
figure legend, the reader is referred to the web ver-
sion of this article.)
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treated with ARA, EPA or both PUFAs contained significantly lower
levels of CPF than cells that only received CPF (one-way ANOVA,
p= .0337 for all comparisons, using imputation values for cells with no
detectable levels of CPF). Accumulation of CPF in the cells correlated
with the transcriptional levels of ppara and fabp3, and with the con-
centration of almost all n-3 and n-6 PUFAs detected in the cells, in-
cluding ARA (20:4), EPA (20:5), and DHA (22:6) (Spearman's rank
correlation analysis, p < .05).
3.6.2. Chlorpyrifos exposure reduced the levels of PUFAs in cells
In the presence of CPF alone, significantly diminished levels of
multiple n-3 and n-6 PUFAs (in total 9 were diminished) including EPA,
DHA, LA, and ARA were observed (Table 1). As expected, co-treatment
with EPA diminished the impact CPF had on n-3 EPA and DPA (Fig. 6A).
Co-treatment with ARA, on the other hand, enhanced the impact CPF
had on DHA, a response not rescued by adding EPA. Similarly, sup-
plementation with ARA counteracted the impact CPF had on n-6 ARA
and adrenate, but not n-3 PUFAs. For the PUFAs, interaction effects
between CPF and ARA were observed for n-6 adrenate and DPA, while
interaction effect between CPF and EPA was only observed for n-3 DPA
(2-way ANOVA, p < .05). These findings suggest that supplementation
of ARA and EPA had low impact on the CPF-induced effects on PUFAs
other than ARA and EPA in the cells.
3.6.3. Monoacylglycerols (MAGs) strongly affected by chlorpyrifos
One of the most distinct effect of CPF was the strong degree of ac-
cumulation of MAGs in exposed cells. Compared to the control, 15
species of MAG were increased in cells exposed to CFP (Table 4). EPA
supplementation resulted in a similar pattern, with 13 MAG species
showing significantly higher concentrations compared to the control. In
contrast, only 3 MAGs were elevated in cells supplemented with ARA
(1-arachidonylglycerol (20:4), 2-arachidonoylglycerol (20:4) and 1-
dihomo-linolenylglycerol (20:3)). Co-treatment with either ARA or EPA
does not seem to have any significant impact on the CPF-induced effect
on MAGs in the cells. CPF treatment also reduced the levels of glycerol
in the cells (Fig. 6B).
Several long-chain fatty acids, palmitoleate (16:1n7), oleate
(18:1n9), myristoleate (14:1n5), 10-heptadecenoate (17:1n7), and cis-
vaccenate (18:1n7), were diminished in CPF-treated hepatocytes com-
pared to controls (Supplementary File 2). As for the MAGs, this trend
was observed in each treatment condition independent of PUFA sup-
plementation or combinatorial treatment.
3.6.4. Reduced energy metabolism
An impact of CPF on energy metabolism was indicated with reduced
levels of the glycogen metabolites maltopentaose, maltotetraose, mal-
totriose, and maltose in exposed cells compared to the controls
(Fig. 6C). This trend was partially rescued in CPF cultures by combi-
natorial treatment with ARA or EPA, but not together. Reduced levels of
glucose in the presence of CPF were accompanied by diminished fruc-
tose 1,6-bisphosphate, dihydroxyacetone phosphate (DHAP), and lac-
tate, indicating a decline in glycolytic metabolism and energy genera-
tion. Similar to glucose, ARA and EPA supplementation alone with CPF,
but not in combination (CPF+ARA+EPA) was able to partially
rescue lactate and pyruvate, indicating a restoration of glycolysis and
energy metabolism. Increased levels of the TCA cycle intermediates
alpha-ketoglutarate, succinate, and fumarate (the latter two with
p < .10) in cells treated with CPF further indicate an impact on overall
energy metabolism (Fig. 6C). ARA and EPA supplementation were able
to restore these energy metabolites to control levels in the presence of
CPF, indicating that supplementation of n-3 and n-6 PUFA can partially
rescue this deficit.
3.6.5. Moderate oxidative stress
A certain degree of oxidative stress was indicated by low levels of
reduced glutathione (GSH) accompanied by modest accumulation of
oxidized glutathione (GSSG), in addition to significantly reduced levels
of cysteine, in CPF-treated cells. Furthermore, significantly diminished
levels of hypotaurine, taurine, and cysteine-glutathione disulfide also
suggested limited cysteine availability or preferential utilization for
glutathione synthesis (Fig. 6D). ARA and EPA supplementation were
not able to counteract this response in the cells.
4. Discussion
In salmonids, it is well known that the cellular fatty acid profile of
tissues such as the liver is highly influenced by both dietary and en-
vironmental factors (Olsvik et al., 2011; Cornet et al., 2018). Supple-
mentation of free fatty acids in the medium will also change the fatty
acid profile of salmonid cells in culture (Ferain et al., 2016). In this
study, the fatty acid profile of the cells supplemented with ARA and
Fig. 4. Total number (A) and total area (B) of lipid
droplets in Atlantic salmon hepatocytes exposed to
chlorpyrifos (CPF), arachidonic acid (ARA), eicosa-
pentaenoic acid (EPA), and combinations of CPF,
ARA and EPA. Primary hepatocyte cells were stained
with Oil Red O and evaluated under light micro-
scopy. Different letters indicate statistical differences
in mean values between the different treatment
groups (one-way ANOVA, p < .05). Values are
mean ± st.dev. (n=6). (For interpretation of the
references to colour in this figure legend, the reader
is referred to the web version of this article.)
Table 2
Size distributions of lipid droplets in Atlantic salmon hepatocytes. Values are
given as mean ± st.dev. (n=6).
Treatment Small Medium Large Very large
<5 μm2 5–15 μm2 15–30 μm2 >30 μm2
Control 71.6 ± 8.7 27.0 ± 15.2 2.5 ± 2.8 0.7 ± 1.8
CPF 48.6 ± 18.9 45.5 ± 10.6 5.4 ± 9.0 0.5 ± 1.1
ARA 44.4 ± 18.1 51.1 ± 17.1⁎ 3.8 ± 2.3 0.7 ± 1.4
CPF+ARA 37.3 ± 16.3⁎⁎ 54.6 ± 13.5⁎ 7.3 ± 4.1 0.8 ± 1.1
EPA 44.7 ± 15.7 50.7 ± 12.1 4.4 ± 4.0 0.2 ± 0.5
CPF+EPA 38.4 ± 13.7⁎⁎ 52.9 ± 13.0⁎ 7.5 ± 2.7 1.2 ± 1.4
CPF+ARA+EPA 47.6 ± 9.0 47.2 ± 7.0 4.5 ± 2.6 0.7 ± 0.9
Asterisks indicate statistical differences in mean values between exposures
within each group of size (one-way ANOVA, p < .05). ⁎p < .05, ⁎⁎p < .01.
Chlorpyrifos (CPF), arachidonic acid (ARA), eicosapentaenoic acid (EPA).
P.A. Olsvik, et al. Toxicology in Vitro 61 (2019) 104655
7
Fig. 5. Venn diagram showing the number of metabolites affected by co-treatment of chlorpyrifos (CPF) and (A) arachidonic acid (ARA) and (B) eicosapentaenoic
acid (EPA). (C) Hierarchical clustering of metabolites.
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EPA clearly reflected this, with elevated levels of n-3 PUFAs in cells
given EPA and n-6 PUFAs in cells given ARA. Lipid droplet staining
confirmed that PUFA supplementation had a profound effect on the
cells. Both the number and size of lipid droplet increased by adding
ARA and EPA. Primary culture of Atlantic salmon hepatocytes therefore
seems to be well suited to study the impact of altered phospholipid
composition on the toxicity of contaminants.
In contrast to PUFA supplementation and combinations between
CPF and PUFAs, exposure to CPF alone did not significantly increase the
number of lipid droplets in the cells. For medium and large-sized lipid
droplets, however, CPF treatment doubled the number, but the increase
was not significant. For small-sized lipid droplets the insecticide re-
duced the number, but again the difference was not significant. This
finding was supported by the metabolite profiling. According to IPA
Core Analysis, “Accumulation of TAG” was reduced in all treatment
groups that received CPF, whereas ARA and EPA supplementation had
no impact on this function. In terms of steatosis with TAG accumulation
in lipid droplets, this study does not document any effect of CPF. The
lack of significant increase in the number of lipid droplets in this study
can rely on the dose, as exposure to high concentrations of OPs re-
portedly can induce accumulation of TAG and emergence of large lipid
droplets in fish liver (Du et al., 2016).
This study clearly demonstrates that exposure to CPF leads to dis-
ruptive lipid metabolism in Atlantic salmon hepatocytes. Most promi-
nently, CPF exposure reduced the levels of 10 different n-3 and n-6
PUFAs and 5 long-chain fatty acids, and lead to accumulation of 15
MAGs in liver cells. This result is broadly in line with our previous
exposure studies with OPs and Atlantic salmon hepatocytes (Olsvik
et al., 2015, 2017). Supplementation with EPA in the exposure medium
did not prevent the CPF-induced impacts on most PUFAs and long-chain
fatty acids, except for increasing the levels of EPA itself and n-3 DPA.
Co-treatment with EPA strengthened the effect on long-chain fatty
acids. While EPA alone only lowered the levels of two long-chain fatty
acids, CPF and EPA together resulted in lower levels of 15 long-chain
fatty acids in the cells. The same pattern was seen for the MAGs. CPF
treatment resulted in elevated levels of 15 MAGs, while EPA supple-
mentation increased the levels of 13 MAGs. CPF and EPA co-treatment
increased the levels of 15 MAGs. In comparison, ARA supplementation
had much less effect on these lipid species. Treatment with ARA had no
effect on the levels of long-chain fatty acids. Apart from increasing the
level of ARA itself 8.5-fold, and subsequently increasing the levels of 4
other n-6 PUFAs (LA, adrenate, n-6 DPA and dihomo-linolenate), ARA
supplementation lowered the level of DHA. The most distinct effect of
co-treatment of both PUFAs and CPF was seen for n-6 DPA. The levels of
n-6 DPA were increased in cells given ARA (7.5-fold) and CPF+ARA
(2.4-fold), but not in cells given CPF+ARA+EPA (−2.0-fold). ARA
supplementation also had less impact on MAG accumulation than CPF
and EPA. Only 3 MAGs were elevated in cells treated with ARA.
Combined treatment with EPA (CPF+ARA+EPA) did not alter this
pattern. Overall, culture supplementation with ARA and/or EPA only
modestly affects the impact CPF has on PUFAs in the cells.
Accumulation of MAGs in CPF-exposed cells suggests a potential
change in complex lipid metabolism that may correlate with reduced
long-chain fatty acid availability. Less TAG will be generated with re-
duced availability of long-chain fatty acids. Alternatively, increased
accumulation of MAGs results from inhibited monoacylglycerol lipase
(MGLL) activity. Indeed, IPA Core Analysis predicted monoacylglycerol
lipase (MGLL) as one of the most significant upstream regulators ex-
plaining the response to CPF treatment. The activation score of MGLL
was predicted decreased to a similar degree in cells exposed to CPF,
CPF+ARA and CPF+EPA. When co-treated with a combination of
both PUFAs, this response disappeared. MGLL is responsible for the
complete hydrolysis of MAGs into glycerol and free fatty acids (Zechner
et al., 2012). Glycerol and glycerol 3-phosphate were both strongly
diminished in cell given all combinations containing CPF, either as a
result of decreased availability of free fatty acids or decreased lipolysis
(or both). Supplementation with PUFAs had no impact on this response,
although EPA alone significantly increased glycerol compared to the
control. Only 2 metabolites directly linked to phospholipid metabolism,
glycerophosphorylcholine (GPC) and glycerophosphoinositol, were
significantly affected by CPF exposure. PUFA supplementation could
not restore the diminished levels of these metabolites in salmon hepa-
tocytes. In addition, 3 lysolipids, 1-palmitoyl-GPC (16:0), 1-palmito-
leoyl-GPC (16:1) and 1-oleoyl-GPC (18:1), were significantly elevated
in cells exposed to CPF. These responses were countered by the PUFAs,
most prominently by EPA.
In addition to increased transcription of ppara and fabp3, there were
several indications of altered β-oxidation of fatty acids in the CPF-ex-
posed cells. Intracellular concentrations of fatty acids and their deri-
vatives are strictly regulated (Reddy and Hashimoto, 2001). Activation
of PPARA, a transcriptional regulator of genes involved in peroxisomal
and mitochondrial β-oxidation, as well as fatty acid transport, has been
shown to improve steatosis and inflammation in rodent models (Staels
et al., 2013). Elevated levels of acetylcarnitine, which contributes to the
movement of acetyl CoA in the mitochondria during lipid oxidation
(Reddy and Hashimoto, 2001), may be indicative of a change in free
carnitine levels as acetylcarnitine is often broken down by esterases to
carnitine in order to support the transport of fatty acids. Furthermore,
low levels of carnitine and deoxycarnitine may suggest a limited ca-
pacity to facilitate mitochondrial β-oxidation as evidenced by low levels
of the ketone body 3-hydroxybutyrate (generated in the presence of
excess acetyl-CoA and historically a marker of fatty acid oxidation).
These perturbation in lipid oxidation were consistent with our previous
study (Olsvik et al., 2015) and were modestly rescued by EPA supple-
mentation alone or in combination with ARA.
In line with our previous study (Olsvik et al., 2015), CPF showed a
distinct effect on many metabolites associated with energy metabolism,
i.e. glycolysis and TCA cycle intermediates. Reduced levels of glycogen
metabolites may reflect decreased glycogen stores or a decline in gly-
cogen degradation that consequently limited glucose levels in these
cells. Furthermore, accumulation of pyruvate in exposed cells point to a
defect in lactate dehydrogenase (LDH) function. The effects on TCA
metabolites may be indicative of mitochondrial dysfunction and po-
tential inhibition of enzymes, as has been reported after exposure to
OPs in fish and human cells (Almeida et al., 2010; Yamada et al., 2017).
ARA and EPA supplementation alone, but not in combination, was able
to partially rescue glycogen degradation, as well as lactate and pyruvate
levels. Taken together, these findings suggest that CPF may limit the
energetic capacity of the liver cells, a mechanism partly restored by n-3
and n-6 PUFA supplementation.
Secondary effects of CPF in fish often include oxidative stress.
Numerous studies have reported that oxidative stress is one of the main
effects of CPF in fish after waterborne exposure (Oruc, 2010; Xing et al.,
2012). In line with the current study, exposure of salmon hepatocytes to
OPs also typically results in diminished levels of reduced GSH and al-
tered levels of cysteine, the rate-limiting metabolite for glutathione
biogenesis (Olsvik et al., 2015). Collectively, these observations
Table 3
Number of significantly affected biochemicals in Atlantic salmon hepatocytes
exposed to chlorpyrifos (CPF) and co-treated with combinations of arachidonic
acid (ARA) and eicosapentaenoic acid (EPA).
Treatment Significantly altered biochemicals Directional response
p < .05 (↑ I ↓)
CPF 102 34 I 68
ARA 31 13 I 18
CPF+ARA 113 25 I 88
EPA 50 19 I 31
CPF+EPA 133 21 I 112
CPF+ARA+EPA 144 34 I 110
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Fig. 6. Pathways affected by chlorpyrifos (CPF), arachidonic acid (ARA), eicosapentaenoic acid (EPA), and combinations of these in Atlantic salmon hepatocytes. (A)
n-3 and n-6 PUFAs, (B) long-chain fatty acids and monoacylglycerol, transport of fatty acids (C) glycolytic metabolism and TCA intermediates and (D) cysteine and
glutathione biogenesis. Graphs shows mean ± SEM (n=6).
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Fig. 6. (continued)
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demonstrate that CPF induces oxidative stress in multiple model sys-
tems. n-3 PUFAs such as EPA has been proposed to have antioxidant
properties (Anderson et al., 2014). For example, in fish liver and kidney
it has been shown that EPA but not ARA enrichment protects the cells
against cadmium and methylmercury, metals that often induce oxida-
tive stress in fish (Nøstbakken et al., 2012; Ferain et al., 2016). How-
ever, neither EPA nor ARA supplementation was able to restore the
levels of GSH in the cells in this study. A similar response was seen in
Atlantic salmon hepatocytes co-treated with CPF and vitamin E (Olsvik
et al., 2015). Vitamin E is a potent fat-soluble antioxidant that protects
cells from production of ROS when fat undergoes oxidation. Supple-
mentation with 100 μM vitamin E (alpha-tocopherol) did however not
restore cysteine metabolism or GSH levels in salmon hepatocytes ex-
posed to CPF (Olsvik et al., 2015).
Of other noticeable CPF-induced metabolic changes restored by
PUFA supplementation, pterin and histidine metabolism can specifi-
cally be mentioned. The cofactor pterin and the related metabolites
biopterin and dihydrobiopterin were significantly reduced in the pre-
sence of CPF. Pterins contribute to the generation of folates (also sig-
nificantly diminished with pesticide treatment) and metabolic processes
including hydroxylation of aromatic compounds, the synthesis of nitric
oxide, respiratory oxidation, and eye pigmentation (Basu and
Burgmayer, 2011). Dihydrobiopterin is a cofactor for the synthesis of
tyrosine and the neurotransmitters dopamine and serotonin. Biopterin
has been linked to neuron degeneration and dopamine deficiency, while
neopterin influences biopterin synthesis and reflects immune activation
(Basu and Burgmayer, 2011). Thus, disruptions in pterin metabolism
and availability may impact multiple biochemical pathways. The CPF-
induced effect on pterin metabolism was rescued by both ARA and EPA
supplementation. Furthermore, elevated levels of histidine and the re-
lated degradation products trans-urocanate and cis-urocanate were
observed in response to CPF treatment. This perturbation did not occur
in the presence of ARA or EPA. In Atlantic salmon hepatocytes co-
treated with CPF and vitamin E, CPF-induced elevated levels of histi-
dine and trans-urocanate were not restored by the antioxidant (Olsvik
et al., 2015). Differences in histidine metabolism can be indicative of
protein turnover and matrix remodeling. In summary, PUFA supple-
mentation obviously has the potential to rescue several mechanisms in
Atlantic salmon liver cells, not only those solely restricted to lipid
metabolism.
Chlorpyrifos is metabolized and detoxified by phase I and II en-
zymes (Hodgson and Rose, 2008). In Atlantic salmon liver cells, we
have previously shown that cyp1a1 is induced at the transcriptional
level at 10 μM but not at 100 μM CPF (Søfteland et al., 2014; Olsvik
et al., 2015). After 30 days of dietary exposure to CPF, EROD activity
was significantly elevated in Atlantic salmon liver (Sanden et al., 2018),
but not in liver of Atlantic cod (Gadus morhua) (Olsvik et al., 2019b). In
this study, however, no significant effects of CPF exposure were seen on
cyp1a1 or CYP1A protein levels. Cholate and deoxycholate, markers of
primary and secondary bile acid metabolism, were significantly ele-
vated in cells exposed to CPF, indicating enhanced detoxification in
exposed cells. The levels of these metabolites were lower in cells co-
treated with PUFAs, probably reflecting lower uptake of CPF in these
cells.
By using hepatocytes from males only, we included vtg as a tran-
scriptional marker of potential endocrine disruption. Exposure to CPF
has been shown to induce VTG in male fish (Manjunatha and Philip,
2016), and we have earlier seen altered transcription of genes asso-
ciated with the Gene Ontology “Response to estrogen stimulus” in
Atlantic salmon hepatocytes exposed to CPF (Olsvik et al., 2015).
However, no significant effect on vtg levels were observed after CPF
exposure in this study.
Table 4
Monoacylglycerol species affected by chlorpyrifos (CPF), arachidonic acid (ARA) and eicosapentaenoic acid (EPA), and their combinations, in Atlantic salmon
hepatocytes. The table shows fold-change ratios (comparisons to the control group). Red (upregulated) p < .05. Pink p < .10/> .05.
        
Monoacylglycerol 
species  CPF ARA CPF+ARA EPA CPF+EPA CPF+ARA+EPA 
        
                
1-myristoylglycerol (14:0)  2.41 2.69 3.03 2.46 2.58 2.49 
2-myristoylglycerol (14:0)  4.60 2.36 3.6 2.17 2.55 1.78 
1-pentadecanoylglycerol (15:0)  1.20 1.22 1.59 1.69 1.33 1.19 
1-palmitoylglycerol (16:0)  2.36 2.05 2.12 2.19 1.89 1.92 
2-palmitoylglycerol (16:0)  3.39 1.95 2.93 2.18 2.85 2.06 
2-stearoylglycerol (18:0)  1.83 1.49 1.45 2.52 1.15 1.94 
1-oleoylglycerol (18:1)  2.05 1.49 1.93 1.82 1.83 1.43 
2-oleoylglycerol (18:1)  3.86 1.22 2.76 1.47 2.48 1.49 
1-linoleoylglycerol (18:2)  3.59 2.65 5.24 3.18 3.79 2.97 
2-linoleoylglycerol (18:2)  4.71 1.18 3.51 1.57 3.07 1.74 
1-linolenoylglycerol (18:3)  4.22 3.3 5.01 2.74 3.90 3.42 
1-arachidonylglycerol (20:4)  7.31 15.53 47.91 3.70 6.63 29.38 
2-arachidonoylglycerol (20:4)  10.07 7.57 30.26 4.18 7.21 16.62 
1-docosahexaenoylglycerol (22:6)  5.88 2.29 6.16 3.45 5.48 4.23 
1-dihomo-linolenylglycerol (20:3)  5.63 3.66 7.58 3.10 4.44 4.31 
2-docosahexaenoylglcyerol*  12.10 2.32 8.29 2.79 6.82 4.97 
1-palmitoleoylglycerol (16:1)*  2.97 2.46 3.74 2.71 3.22 2.40 
2-palmitoleoylglycerol (16:1)*  5.55 1.88 4.20 1.77 3.42 2.24 
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In conclusion, this study shows that CPF exposure leads to reduced
levels of several PUFAs and long-chain fatty acids, and mitigate accu-
mulation of MAGs in Atlantic salmon hepatocytes. Supplementation
with ARA and EPA could not prevent CPF-induced accumulation of
MAGs in the cells, and had only minor impact on other affected lipid
species. Most profoundly, co-treatment with PUFAs partly restored the
negative effect CPF had on energy metabolism. PUFA supplementation
did not counteract CPF-induced oxidative stress.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.tiv.2019.104655.
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